Treatment combinations targeting apoptosis to improve immunotherapy of melanoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-06-24

AUTHORS

Peter Hersey, Xu Dong Zhang

ABSTRACT

Immunotherapy based on T cell responses to the tumor is believed to involve killing of cancer cells by induction of apoptosis. The predominant mechanisms are death ligand-induced signaling mainly by TNF-related apoptosis-inducing ligand (TRAIL) mediated by CD4 T cells, monocytes and dendritic cells, and perforin/granzyme mediated apoptosis mediated by CD8 T cells and NK cells. Resistance against TRAIL involves loss of TRAIL death receptors and/or activation of the MEK and/or Akt signal pathways. Resistance to CD8 CTL responses also involves activation of the MEK and/or Akt pathways. Apoptosis induced by immune responses is regulated by the Bcl-2 family of proteins. Many reagents have been developed against the Bcl-2 antiapoptotic proteins and clinical trials combining them with immunotherapy are awaited. The second group of agents that regulate the Bcl-2 family of proteins are the signal pathway inhibitors. Clinical trials with inhibitors of RAS, RAF or MEK are in progress and would appear an exciting combination with immunotherapy. One of the main drivers of resistance to apoptosis are adaptive mechanisms that allow cancer cells to overcome endoplasmic reticulum (ER) stress. These adaptive mechanisms inhibit practically all known apoptotic pathways and create an acidic environment that may reduce infiltration of lymphocytes against the tumor. The signal pathway inhibitors may be effective against these adaptive processes but additional agents that target ER stress pathways are in development. In conclusion, combination of immunotherapy with agents that target antiapoptotic mechanisms in cancer cells offers a new approach that requires evaluation in clinical trials. More... »

PAGES

1749-1759

References to SciGraph publications

  • 1993-10. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression in BRITISH JOURNAL OF CANCER
  • 2008-10-20. FLIP and the death effector domain family in ONCOGENE
  • 2004-12-16. The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients in LEUKEMIA
  • 2008-01-14. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole in ONCOGENE
  • 2008-05-10. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2009-03-18. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2003-06-17. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB in ONCOGENE
  • 2008-10-19. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis in NATURE CELL BIOLOGY
  • 2002-06-01. Targeting death and decoy receptors of the tumour-necrosis factor superfamily in NATURE REVIEWS CANCER
  • 2008-10-10. Tumour cell survival signalling by the ERK1/2 pathway in CELL DEATH & DIFFERENTIATION
  • 2007-06-19. The inhibitors of apoptosis (IAPs) as cancer targets in APOPTOSIS
  • 2009-01-20. Integrating BRAF/MEK inhibitors into combination therapy for melanoma in BRITISH JOURNAL OF CANCER
  • 2001-11-01. How melanoma cells evade trail-induced apoptosis in NATURE REVIEWS CANCER
  • 2007. Therapeutic Vaccination for the Treatment of Malignant Melanoma in TARGETED THERAPIES IN CANCER
  • 2006-12-01. Perforin-mediated target-cell death and immune homeostasis in NATURE REVIEWS IMMUNOLOGY
  • 2002-09-01. The Bcl2 family: regulators of the cellular life-or-death switch in NATURE REVIEWS CANCER
  • 2007-02-20. Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction in BRITISH JOURNAL OF CANCER
  • 2008-02-01. TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2 in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2003-05-15. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria in ONCOGENE
  • 2004-11-15. Ras-dependent induction of HIF-1α785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion in ONCOGENE
  • 2008-11-07. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists in NATURE REVIEWS DRUG DISCOVERY
  • 2001-10-30. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling in CELL DEATH & DIFFERENTIATION
  • 2007-03-26. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma in MODERN PATHOLOGY
  • 2006-01-13. Role of the unfolded protein response in cell death in APOPTOSIS
  • 2005-05-01. Regulators of apoptosis: suitable targets for immune therapy of cancer in NATURE REVIEWS DRUG DISCOVERY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00262-009-0732-5

    DOI

    http://dx.doi.org/10.1007/s00262-009-0732-5

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1004077836

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/19551381


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Apoptosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Endoplasmic Reticulum", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mitogen-Activated Protein Kinase Kinases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myeloid Cell Leukemia Sequence 1 Protein", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins c-bcl-2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, TNF-Related Apoptosis-Inducing Ligand", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "T-Lymphocytes, Cytotoxic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "TNF-Related Apoptosis-Inducing Ligand", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, 2300, Newcastle, NSW, Australia", 
              "id": "http://www.grid.ac/institutes/grid.413265.7", 
              "name": [
                "Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, 2300, Newcastle, NSW, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hersey", 
            "givenName": "Peter", 
            "id": "sg:person.01073667716.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, 2300, Newcastle, NSW, Australia", 
              "id": "http://www.grid.ac/institutes/grid.413265.7", 
              "name": [
                "Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, 2300, Newcastle, NSW, Australia"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhang", 
            "givenName": "Xu Dong", 
            "id": "sg:person.01210116316.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/35101078", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021222128", 
              "https://doi.org/10.1038/35101078"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-008-7513-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024912225", 
              "https://doi.org/10.1007/s00018-008-7513-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncb1789", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045912113", 
              "https://doi.org/10.1038/ncb1789"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6603599", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032758390", 
              "https://doi.org/10.1038/sj.bjc.6603599"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd1717", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007730581", 
              "https://doi.org/10.1038/nrd1717"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc883", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008451806", 
              "https://doi.org/10.1038/nrc883"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nri1983", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026188939", 
              "https://doi.org/10.1038/nri1983"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2008.299", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005671810", 
              "https://doi.org/10.1038/onc.2008.299"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10495-005-3088-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045885620", 
              "https://doi.org/10.1007/s10495-005-3088-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc821", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047196539", 
              "https://doi.org/10.1038/nrc821"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005309379", 
              "https://doi.org/10.1038/sj.onc.1208003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1479-5876-6-24", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048809078", 
              "https://doi.org/10.1186/1479-5876-6-24"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6604891", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010956534", 
              "https://doi.org/10.1038/sj.bjc.6604891"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-540-46091-6_19", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030164359", 
              "https://doi.org/10.1007/978-3-540-46091-6_19"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10495-007-0087-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019546909", 
              "https://doi.org/10.1007/s10495-007-0087-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd2637", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032375076", 
              "https://doi.org/10.1038/nrd2637"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1211008", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045410141", 
              "https://doi.org/10.1038/sj.onc.1211008"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00262-009-0691-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001734922", 
              "https://doi.org/10.1007/s00262-009-0691-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206520", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021041727", 
              "https://doi.org/10.1038/sj.onc.1206520"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cdd.4400943", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031009974", 
              "https://doi.org/10.1038/sj.cdd.4400943"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206427", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050315555", 
              "https://doi.org/10.1038/sj.onc.1206427"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cdd.2008.148", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043432644", 
              "https://doi.org/10.1038/cdd.2008.148"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/modpathol.3800750", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022673157", 
              "https://doi.org/10.1038/modpathol.3800750"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1993.422", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015319141", 
              "https://doi.org/10.1038/bjc.1993.422"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2403621", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034260389", 
              "https://doi.org/10.1038/sj.leu.2403621"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2009-06-24", 
        "datePublishedReg": "2009-06-24", 
        "description": "Immunotherapy based on T cell responses to the tumor is believed to involve killing of cancer cells by induction of apoptosis. The predominant mechanisms are death ligand-induced signaling mainly by TNF-related apoptosis-inducing ligand (TRAIL) mediated by CD4 T cells, monocytes and dendritic cells, and perforin/granzyme mediated apoptosis mediated by CD8 T cells and NK cells. Resistance against TRAIL involves loss of TRAIL death receptors and/or activation of the MEK and/or Akt signal pathways. Resistance to CD8 CTL responses also involves activation of the MEK and/or Akt pathways. Apoptosis induced by immune responses is regulated by the Bcl-2 family of proteins. Many reagents have been developed against the Bcl-2 antiapoptotic proteins and clinical trials combining them with immunotherapy are awaited. The second group of agents that regulate the Bcl-2 family of proteins are the signal pathway inhibitors. Clinical trials with inhibitors of RAS, RAF or MEK are in progress and would appear an exciting combination with immunotherapy. One of the main drivers of resistance to apoptosis are adaptive mechanisms that allow cancer cells to overcome endoplasmic reticulum (ER) stress. These adaptive mechanisms inhibit practically all known apoptotic pathways and create an acidic environment that may reduce infiltration of lymphocytes against the tumor. The signal pathway inhibitors may be effective against these adaptive processes but additional agents that target ER stress pathways are in development. In conclusion, combination of immunotherapy with agents that target antiapoptotic mechanisms in cancer cells offers a new approach that requires evaluation in clinical trials.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00262-009-0732-5", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096240", 
            "issn": [
              "0340-7004", 
              "1432-0851"
            ], 
            "name": "Cancer Immunology, Immunotherapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "58"
          }
        ], 
        "keywords": [
          "Bcl-2 family", 
          "signal pathway inhibitors", 
          "cancer cells", 
          "Bcl-2 antiapoptotic protein", 
          "adaptive mechanisms", 
          "clinical trials", 
          "pathway inhibitor", 
          "induction of apoptosis", 
          "ER stress pathway", 
          "endoplasmic reticulum stress", 
          "TRAIL death receptors", 
          "Akt signal pathway", 
          "inhibitors of RAS", 
          "apoptosis-inducing ligand", 
          "death receptors", 
          "T cells", 
          "apoptotic pathway", 
          "antiapoptotic proteins", 
          "Akt pathway", 
          "stress pathways", 
          "signal pathway", 
          "CD8 CTL responses", 
          "CD8 T cells", 
          "immunotherapy of melanoma", 
          "T cell responses", 
          "reticulum stress", 
          "combination of immunotherapy", 
          "CD4 T cells", 
          "MEK", 
          "infiltration of lymphocytes", 
          "apoptosis", 
          "perforin/granzyme", 
          "protein", 
          "antiapoptotic mechanisms", 
          "pathway", 
          "NK cells", 
          "CTL responses", 
          "dendritic cells", 
          "cells", 
          "adaptive process", 
          "immune response", 
          "immunotherapy", 
          "cell responses", 
          "inhibitors", 
          "additional agents", 
          "activation", 
          "trials", 
          "family", 
          "main drivers", 
          "second group", 
          "tumors", 
          "Raf", 
          "mechanism", 
          "signaling", 
          "acidic environment", 
          "predominant mechanism", 
          "treatment combinations", 
          "exciting combination", 
          "resistance", 
          "agents", 
          "response", 
          "RAS", 
          "induction", 
          "TNF", 
          "receptors", 
          "lymphocytes", 
          "melanoma", 
          "monocytes", 
          "granzymes", 
          "death", 
          "killing", 
          "infiltration", 
          "stress", 
          "ligands", 
          "conclusion", 
          "combination", 
          "group", 
          "trails", 
          "drivers", 
          "loss", 
          "development", 
          "evaluation", 
          "environment", 
          "progress", 
          "reagents", 
          "process", 
          "new approach", 
          "approach"
        ], 
        "name": "Treatment combinations targeting apoptosis to improve immunotherapy of melanoma", 
        "pagination": "1749-1759", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1004077836"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00262-009-0732-5"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "19551381"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00262-009-0732-5", 
          "https://app.dimensions.ai/details/publication/pub.1004077836"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T15:53", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_480.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00262-009-0732-5"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-009-0732-5'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-009-0732-5'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-009-0732-5'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-009-0732-5'


     

    This table displays all metadata directly associated to this object as RDF triples.

    304 TRIPLES      21 PREDICATES      150 URIs      117 LITERALS      19 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00262-009-0732-5 schema:about N1d7b731289e9452eb8ed36b722c1e5f7
    2 N356e0c7e1488405d91e704892adc23cd
    3 N5f9accb0ff1544519a495f5a16904e38
    4 N63fc075041554cddabbc9b2a0d31e706
    5 N798882c9ea5b4701970248e4446b6c74
    6 N867693de83ab49159203ebd61efbd8d8
    7 N8ba99aec78674bc183f561fd3e464672
    8 N9b6a7d2f030642f682ed4d41152eaada
    9 Nac7b4852712d46b7905b9088a6cec915
    10 Ne5f69efba73d4185b714b6ffe96b79ed
    11 Nfc3cbfcfd24049b6bcf711c6a0ab7cd7
    12 Nfc54bb25998f436abda8c474ebe23f30
    13 anzsrc-for:11
    14 anzsrc-for:1107
    15 schema:author N0af935fdaf294e418b96e0c5d98bf9f4
    16 schema:citation sg:pub.10.1007/978-3-540-46091-6_19
    17 sg:pub.10.1007/s00018-008-7513-8
    18 sg:pub.10.1007/s00262-009-0691-x
    19 sg:pub.10.1007/s10495-005-3088-0
    20 sg:pub.10.1007/s10495-007-0087-3
    21 sg:pub.10.1038/35101078
    22 sg:pub.10.1038/bjc.1993.422
    23 sg:pub.10.1038/cdd.2008.148
    24 sg:pub.10.1038/modpathol.3800750
    25 sg:pub.10.1038/ncb1789
    26 sg:pub.10.1038/nrc821
    27 sg:pub.10.1038/nrc883
    28 sg:pub.10.1038/nrd1717
    29 sg:pub.10.1038/nrd2637
    30 sg:pub.10.1038/nri1983
    31 sg:pub.10.1038/onc.2008.299
    32 sg:pub.10.1038/sj.bjc.6603599
    33 sg:pub.10.1038/sj.bjc.6604891
    34 sg:pub.10.1038/sj.cdd.4400943
    35 sg:pub.10.1038/sj.leu.2403621
    36 sg:pub.10.1038/sj.onc.1206427
    37 sg:pub.10.1038/sj.onc.1206520
    38 sg:pub.10.1038/sj.onc.1208003
    39 sg:pub.10.1038/sj.onc.1211008
    40 sg:pub.10.1186/1479-5876-6-24
    41 schema:datePublished 2009-06-24
    42 schema:datePublishedReg 2009-06-24
    43 schema:description Immunotherapy based on T cell responses to the tumor is believed to involve killing of cancer cells by induction of apoptosis. The predominant mechanisms are death ligand-induced signaling mainly by TNF-related apoptosis-inducing ligand (TRAIL) mediated by CD4 T cells, monocytes and dendritic cells, and perforin/granzyme mediated apoptosis mediated by CD8 T cells and NK cells. Resistance against TRAIL involves loss of TRAIL death receptors and/or activation of the MEK and/or Akt signal pathways. Resistance to CD8 CTL responses also involves activation of the MEK and/or Akt pathways. Apoptosis induced by immune responses is regulated by the Bcl-2 family of proteins. Many reagents have been developed against the Bcl-2 antiapoptotic proteins and clinical trials combining them with immunotherapy are awaited. The second group of agents that regulate the Bcl-2 family of proteins are the signal pathway inhibitors. Clinical trials with inhibitors of RAS, RAF or MEK are in progress and would appear an exciting combination with immunotherapy. One of the main drivers of resistance to apoptosis are adaptive mechanisms that allow cancer cells to overcome endoplasmic reticulum (ER) stress. These adaptive mechanisms inhibit practically all known apoptotic pathways and create an acidic environment that may reduce infiltration of lymphocytes against the tumor. The signal pathway inhibitors may be effective against these adaptive processes but additional agents that target ER stress pathways are in development. In conclusion, combination of immunotherapy with agents that target antiapoptotic mechanisms in cancer cells offers a new approach that requires evaluation in clinical trials.
    44 schema:genre article
    45 schema:isAccessibleForFree true
    46 schema:isPartOf N0b6979f4c24f46e5a5afb139bda3d462
    47 N6d37a03c01254eeea7fef9d1242d764f
    48 sg:journal.1096240
    49 schema:keywords Akt pathway
    50 Akt signal pathway
    51 Bcl-2 antiapoptotic protein
    52 Bcl-2 family
    53 CD4 T cells
    54 CD8 CTL responses
    55 CD8 T cells
    56 CTL responses
    57 ER stress pathway
    58 MEK
    59 NK cells
    60 RAS
    61 Raf
    62 T cell responses
    63 T cells
    64 TNF
    65 TRAIL death receptors
    66 acidic environment
    67 activation
    68 adaptive mechanisms
    69 adaptive process
    70 additional agents
    71 agents
    72 antiapoptotic mechanisms
    73 antiapoptotic proteins
    74 apoptosis
    75 apoptosis-inducing ligand
    76 apoptotic pathway
    77 approach
    78 cancer cells
    79 cell responses
    80 cells
    81 clinical trials
    82 combination
    83 combination of immunotherapy
    84 conclusion
    85 death
    86 death receptors
    87 dendritic cells
    88 development
    89 drivers
    90 endoplasmic reticulum stress
    91 environment
    92 evaluation
    93 exciting combination
    94 family
    95 granzymes
    96 group
    97 immune response
    98 immunotherapy
    99 immunotherapy of melanoma
    100 induction
    101 induction of apoptosis
    102 infiltration
    103 infiltration of lymphocytes
    104 inhibitors
    105 inhibitors of RAS
    106 killing
    107 ligands
    108 loss
    109 lymphocytes
    110 main drivers
    111 mechanism
    112 melanoma
    113 monocytes
    114 new approach
    115 pathway
    116 pathway inhibitor
    117 perforin/granzyme
    118 predominant mechanism
    119 process
    120 progress
    121 protein
    122 reagents
    123 receptors
    124 resistance
    125 response
    126 reticulum stress
    127 second group
    128 signal pathway
    129 signal pathway inhibitors
    130 signaling
    131 stress
    132 stress pathways
    133 trails
    134 treatment combinations
    135 trials
    136 tumors
    137 schema:name Treatment combinations targeting apoptosis to improve immunotherapy of melanoma
    138 schema:pagination 1749-1759
    139 schema:productId Nc08f6ed7f588426fa9f5fc574246d439
    140 Nc8041cedc0994900a395aa78ff1c01ec
    141 Nde2c27bd1de84ba7a8ad8a960f27532e
    142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004077836
    143 https://doi.org/10.1007/s00262-009-0732-5
    144 schema:sdDatePublished 2022-09-02T15:53
    145 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    146 schema:sdPublisher Nd044b2a06b3040ff8d17a458a79e7680
    147 schema:url https://doi.org/10.1007/s00262-009-0732-5
    148 sgo:license sg:explorer/license/
    149 sgo:sdDataset articles
    150 rdf:type schema:ScholarlyArticle
    151 N0af935fdaf294e418b96e0c5d98bf9f4 rdf:first sg:person.01073667716.42
    152 rdf:rest Nd1deb58eaf5741acb1179bcc8be33fbf
    153 N0b6979f4c24f46e5a5afb139bda3d462 schema:issueNumber 11
    154 rdf:type schema:PublicationIssue
    155 N1d7b731289e9452eb8ed36b722c1e5f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Melanoma
    157 rdf:type schema:DefinedTerm
    158 N356e0c7e1488405d91e704892adc23cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Apoptosis
    160 rdf:type schema:DefinedTerm
    161 N5f9accb0ff1544519a495f5a16904e38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Receptors, TNF-Related Apoptosis-Inducing Ligand
    163 rdf:type schema:DefinedTerm
    164 N63fc075041554cddabbc9b2a0d31e706 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name Mitogen-Activated Protein Kinase Kinases
    166 rdf:type schema:DefinedTerm
    167 N6d37a03c01254eeea7fef9d1242d764f schema:volumeNumber 58
    168 rdf:type schema:PublicationVolume
    169 N798882c9ea5b4701970248e4446b6c74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name T-Lymphocytes, Cytotoxic
    171 rdf:type schema:DefinedTerm
    172 N867693de83ab49159203ebd61efbd8d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Endoplasmic Reticulum
    174 rdf:type schema:DefinedTerm
    175 N8ba99aec78674bc183f561fd3e464672 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Proto-Oncogene Proteins c-bcl-2
    177 rdf:type schema:DefinedTerm
    178 N9b6a7d2f030642f682ed4d41152eaada schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Myeloid Cell Leukemia Sequence 1 Protein
    180 rdf:type schema:DefinedTerm
    181 Nac7b4852712d46b7905b9088a6cec915 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Immunotherapy
    183 rdf:type schema:DefinedTerm
    184 Nc08f6ed7f588426fa9f5fc574246d439 schema:name pubmed_id
    185 schema:value 19551381
    186 rdf:type schema:PropertyValue
    187 Nc8041cedc0994900a395aa78ff1c01ec schema:name dimensions_id
    188 schema:value pub.1004077836
    189 rdf:type schema:PropertyValue
    190 Nd044b2a06b3040ff8d17a458a79e7680 schema:name Springer Nature - SN SciGraph project
    191 rdf:type schema:Organization
    192 Nd1deb58eaf5741acb1179bcc8be33fbf rdf:first sg:person.01210116316.18
    193 rdf:rest rdf:nil
    194 Nde2c27bd1de84ba7a8ad8a960f27532e schema:name doi
    195 schema:value 10.1007/s00262-009-0732-5
    196 rdf:type schema:PropertyValue
    197 Ne5f69efba73d4185b714b6ffe96b79ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Humans
    199 rdf:type schema:DefinedTerm
    200 Nfc3cbfcfd24049b6bcf711c6a0ab7cd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    201 schema:name Signal Transduction
    202 rdf:type schema:DefinedTerm
    203 Nfc54bb25998f436abda8c474ebe23f30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    204 schema:name TNF-Related Apoptosis-Inducing Ligand
    205 rdf:type schema:DefinedTerm
    206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    207 schema:name Medical and Health Sciences
    208 rdf:type schema:DefinedTerm
    209 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    210 schema:name Immunology
    211 rdf:type schema:DefinedTerm
    212 sg:journal.1096240 schema:issn 0340-7004
    213 1432-0851
    214 schema:name Cancer Immunology, Immunotherapy
    215 schema:publisher Springer Nature
    216 rdf:type schema:Periodical
    217 sg:person.01073667716.42 schema:affiliation grid-institutes:grid.413265.7
    218 schema:familyName Hersey
    219 schema:givenName Peter
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073667716.42
    221 rdf:type schema:Person
    222 sg:person.01210116316.18 schema:affiliation grid-institutes:grid.413265.7
    223 schema:familyName Zhang
    224 schema:givenName Xu Dong
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210116316.18
    226 rdf:type schema:Person
    227 sg:pub.10.1007/978-3-540-46091-6_19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030164359
    228 https://doi.org/10.1007/978-3-540-46091-6_19
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1007/s00018-008-7513-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024912225
    231 https://doi.org/10.1007/s00018-008-7513-8
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1007/s00262-009-0691-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001734922
    234 https://doi.org/10.1007/s00262-009-0691-x
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1007/s10495-005-3088-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045885620
    237 https://doi.org/10.1007/s10495-005-3088-0
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1007/s10495-007-0087-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019546909
    240 https://doi.org/10.1007/s10495-007-0087-3
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1038/35101078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021222128
    243 https://doi.org/10.1038/35101078
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1038/bjc.1993.422 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015319141
    246 https://doi.org/10.1038/bjc.1993.422
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1038/cdd.2008.148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043432644
    249 https://doi.org/10.1038/cdd.2008.148
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1038/modpathol.3800750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022673157
    252 https://doi.org/10.1038/modpathol.3800750
    253 rdf:type schema:CreativeWork
    254 sg:pub.10.1038/ncb1789 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045912113
    255 https://doi.org/10.1038/ncb1789
    256 rdf:type schema:CreativeWork
    257 sg:pub.10.1038/nrc821 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047196539
    258 https://doi.org/10.1038/nrc821
    259 rdf:type schema:CreativeWork
    260 sg:pub.10.1038/nrc883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008451806
    261 https://doi.org/10.1038/nrc883
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1038/nrd1717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007730581
    264 https://doi.org/10.1038/nrd1717
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1038/nrd2637 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032375076
    267 https://doi.org/10.1038/nrd2637
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1038/nri1983 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026188939
    270 https://doi.org/10.1038/nri1983
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1038/onc.2008.299 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005671810
    273 https://doi.org/10.1038/onc.2008.299
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1038/sj.bjc.6603599 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032758390
    276 https://doi.org/10.1038/sj.bjc.6603599
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1038/sj.bjc.6604891 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010956534
    279 https://doi.org/10.1038/sj.bjc.6604891
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1038/sj.cdd.4400943 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031009974
    282 https://doi.org/10.1038/sj.cdd.4400943
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1038/sj.leu.2403621 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034260389
    285 https://doi.org/10.1038/sj.leu.2403621
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1038/sj.onc.1206427 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050315555
    288 https://doi.org/10.1038/sj.onc.1206427
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1038/sj.onc.1206520 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021041727
    291 https://doi.org/10.1038/sj.onc.1206520
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1038/sj.onc.1208003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005309379
    294 https://doi.org/10.1038/sj.onc.1208003
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1038/sj.onc.1211008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045410141
    297 https://doi.org/10.1038/sj.onc.1211008
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1186/1479-5876-6-24 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048809078
    300 https://doi.org/10.1186/1479-5876-6-24
    301 rdf:type schema:CreativeWork
    302 grid-institutes:grid.413265.7 schema:alternateName Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, 2300, Newcastle, NSW, Australia
    303 schema:name Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, 2300, Newcastle, NSW, Australia
    304 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...